caredx - CDNA
CDNA
Close Chg Chg %
17.64 1.26 7.14%
Closed Market
18.90
+1.26 (7.14%)
Volume: 877.34K
Last Updated:
Mar 14, 2025, 4:00 PM EDT
Company Overview: caredx - CDNA
CDNA Key Data
| Open $17.88 | Day Range 17.88 - 18.92 |
| 52 Week Range 7.42 - 34.84 | Market Cap $977.71M |
| Shares Outstanding 55.43M | Public Float 51.92M |
| Beta 1.95 | Rev. Per Employee N/A |
| P/E Ratio 20.39 | EPS $1.13 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 902.29K |
CDNA Performance
| 1 Week | -6.77% | ||
| 1 Month | -28.00% | ||
| 3 Months | -22.83% | ||
| 1 Year | 73.96% | ||
| 5 Years | -11.58% |
CDNA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About caredx - CDNA
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
CDNA At a Glance
CareDx, Inc.
8000 Marina Boulevard
Brisbane, California 94005
| Phone | 1-415-287-2300 | Revenue | 333.79M | |
| Industry | Medical Specialties | Net Income | 52.55M | |
| Sector | Health Technology | 2024 Sales Growth | 19.071% | |
| Fiscal Year-end | 12 / 2025 | Employees | 650 | |
| View SEC Filings |
CDNA Valuation
| P/E Current | 20.386 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.069 |
| Price to Sales Ratio | 3.632 |
| Price to Book Ratio | 3.099 |
| Price to Cash Flow Ratio | 31.861 |
| Enterprise Value to EBITDA | -29.242 |
| Enterprise Value to Sales | 2.936 |
| Total Debt to Enterprise Value | 0.029 |
CDNA Efficiency
| Revenue/Employee | 513,515.385 |
| Income Per Employee | 80,844.615 |
| Receivables Turnover | 5.167 |
| Total Asset Turnover | 0.674 |
CDNA Liquidity
| Current Ratio | 3.937 |
| Quick Ratio | 3.719 |
| Cash Ratio | 2.917 |
CDNA Profitability
| Gross Margin | 66.401 |
| Operating Margin | -15.959 |
| Pretax Margin | 15.836 |
| Net Margin | 15.743 |
| Return on Assets | 10.615 |
| Return on Equity | 16.428 |
| Return on Total Capital | 12.918 |
| Return on Invested Capital | 15.225 |
CDNA Capital Structure
| Total Debt to Total Equity | 7.496 |
| Total Debt to Total Capital | 6.973 |
| Total Debt to Total Assets | 5.612 |
| Long-Term Debt to Equity | 5.883 |
| Long-Term Debt to Total Capital | 5.473 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Caredx - CDNA
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 296.40M | 321.79M | 280.32M | 333.79M | |
Sales Growth
| +54.22% | +8.57% | -12.89% | +19.07% | |
Cost of Goods Sold (COGS) incl D&A
| 98.99M | 114.46M | 104.46M | 112.15M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 11.88M | 16.01M | 19.82M | 19.76M | |
Depreciation
| 6.08M | 9.78M | 13.36M | 13.41M | |
Amortization of Intangibles
| 5.80M | 6.23M | 6.47M | 6.35M | |
COGS Growth
| +53.19% | +15.63% | -8.74% | +7.37% | |
Gross Income
| 197.41M | 207.33M | 175.87M | 221.63M | |
Gross Income Growth
| +54.74% | +5.03% | -15.17% | +26.02% | |
Gross Profit Margin
| +66.60% | +64.43% | +62.74% | +66.40% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 226.83M | 284.56M | 277.77M | 274.90M | |
Research & Development
| 76.53M | 90.39M | 81.87M | 72.41M | |
Other SG&A
| 150.31M | 194.17M | 195.90M | 202.50M | |
SGA Growth
| +51.12% | +25.45% | -2.39% | -1.03% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 1.94M | 2.82M | 101.45M | (94.03M) | |
EBIT after Unusual Expense
| (31.36M) | (80.05M) | (203.35M) | 40.77M | |
Non Operating Income/Expense
| (725.00K) | 3.81M | 13.21M | 12.09M | |
Non-Operating Interest Income
| 160.00K | 3.76M | 11.87M | 11.77M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (32.09M) | (76.23M) | (190.14M) | 52.86M | |
Pretax Income Growth
| -62.47% | -137.58% | -149.42% | +127.80% | |
Pretax Margin
| -10.83% | -23.69% | -67.83% | +15.84% | |
Income Tax
| (1.43M) | 379.00K | 141.00K | 310.00K | |
Income Tax - Current - Domestic
| 91.00K | 473.00K | 69.00K | 200.00K | |
Income Tax - Current - Foreign
| - | (139.00K) | 184.00K | 9.00K | |
Income Tax - Deferred - Domestic
| (536.00K) | (55.00K) | 72.00K | (36.00K) | |
Income Tax - Deferred - Foreign
| - | (842.00K) | (223.00K) | 137.00K | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (30.66M) | (76.61M) | (190.28M) | 52.55M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (30.66M) | (76.61M) | (190.28M) | 52.55M | |
Net Income Growth
| -63.85% | -149.86% | -148.37% | +127.62% | |
Net Margin Growth
| -10.34% | -23.81% | -67.88% | +15.74% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (30.66M) | (76.61M) | (190.28M) | 52.55M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (30.66M) | (76.61M) | (190.28M) | 52.55M | |
EPS (Basic)
| -0.5869 | -1.4368 | -3.5392 | 0.9958 | |
EPS (Basic) Growth
| -45.78% | -144.81% | -146.33% | +128.14% | |
Basic Shares Outstanding
| 52.24M | 53.32M | 53.76M | 52.77M | |
EPS (Diluted)
| -0.5869 | -1.4368 | -3.5392 | 0.9281 | |
EPS (Diluted) Growth
| -45.78% | -144.81% | -146.33% | +126.22% | |
Diluted Shares Outstanding
| 52.24M | 53.32M | 53.76M | 56.62M | |
EBITDA
| (17.54M) | (61.22M) | (82.08M) | (33.51M) | |
EBITDA Growth
| -35.10% | -249.03% | -34.06% | +59.17% | |
EBITDA Margin
| -5.92% | -19.03% | -29.28% | -10.04% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 32.188 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.207 | |
| FY Report Date | 03 / 2025 | Current Year's Estimate | -0.45 | |
| Last Quarter’s Earnings | 1.51 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.93 | Next Fiscal Year Estimate | -0.016 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 6 | 6 | 5 |
| Mean Estimate | -0.21 | -0.14 | -0.45 | -0.02 |
| High Estimates | -0.16 | -0.09 | -0.20 | 0.25 |
| Low Estimate | -0.25 | -0.19 | -0.62 | -0.13 |
| Coefficient of Variance | -16.67 | -25.63 | -32.84 | -1,045.45 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 4 | 4 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Caredx - CDNA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Caredx - CDNA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 23, 2024 | Alexander L. Johnson See Remarks | 49,569 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 23, 2024 | Alexander L. Johnson See Remarks | 71,126 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 23, 2024 | Alexander L. Johnson See Remarks | 284,983 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.58 per share | 9,284,746.14 |
| Aug 23, 2024 | Alexander L. Johnson See Remarks | 306,540 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $23.48 per share | 7,197,559.20 |
| Aug 23, 2024 | Alexander L. Johnson See Remarks | 284,983 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.17 per share | 9,452,886.11 |
| Aug 23, 2024 | Alexander L. Johnson See Remarks | 324,449 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $23.48 per share | 7,618,062.52 |
| Aug 23, 2024 | Peter K. Maag Director | 2,428 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 23, 2024 | Peter K. Maag Director | 330,024 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $32.67 per share | 10,781,884.08 |
| Aug 23, 2024 | Peter K. Maag Director | 365,576 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $7.96 per share | 2,909,984.96 |
| Aug 23, 2024 | Peter K. Maag Director | 356,732 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.23 per share | 11,854,204.36 |
| Aug 23, 2024 | Peter K. Maag Director | 342,842 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.25 per share | 11,399,496.50 |
| Jul 11, 2024 | Jeffrey A. Novack Secretary and General Counsel | 123,173 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.59 per share | 1,920,267.07 |
| Jul 11, 2024 | Michael D. Goldberg Director | 138,235 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 25, 2024 | William A. Hagstrom Director | 16,048 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | R. Bryan Riggsbee Director | 16,048 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Hannah A. Valantine Director | 16,048 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Fred Ehrenkranz Cohen Director | 16,048 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | Arthur A. Torres Director | 16,048 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | George W. Bickerstaff Director | 16,048 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 21, 2024 | R. Bryan Riggsbee Director | 9,760 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |